University of Leicester
Browse
DOCUMENT
Global Burden of Cancer 2017_appendix.pdf (8.79 MB)
DOCUMENT
Figures.pdf (8.24 MB)
DOCUMENT
jamaoncology_fitzmaurice_2019_oi_190065.pdf (1.44 MB)
1/0
3 files

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study.

journal contribution
posted on 2019-10-02, 13:44 authored by Global Burden of Disease Cancer Collaboration, C Fitzmaurice, D Abate, N Abbasi, H Abbastabar, F Abd-Allah, O Abdel-Rahman, A Abdelalim, A Abdoli, I Abdollahpour, ASM Abdulle, ND Abebe, HN Abraha, LJ Abu-Raddad, A Abualhasan, IA Adedeji, SM Advani, M Afarideh, M Afshari, M Aghaali, D Agius, S Agrawal, A Ahmadi, E Ahmadian, E Ahmadpour, MB Ahmed, ME Akbari, T Akinyemiju, Z Al-Aly, AM AlAbdulKader, F Alahdab, T Alam, GM Alamene, BTT Alemnew, KA Alene, C Alinia, V Alipour, SM Aljunid, FA Bakeshei, MAH Almadi, A Almasi-Hashiani, U Alsharif, S Alsowaidi, N Alvis-Guzman, E Amini, S Amini, YA Amoako, Z Anbari, NH Anber, CL Andrei, M Anjomshoa, F Ansari, A Ansariadi, SCY Appiah, M Arab-Zozani, J Arabloo, Z Arefi, O Aremu, HA Areri, A Artaman, H Asayesh, ET Asfaw, AF Ashagre, R Assadi, B Ataeinia, HT Atalay, Z Ataro, S Atique, M Ausloos, L Avila-Burgos, EFGA Avokpaho, A Awasthi, N Awoke, BP Ayala Quintanilla, MA Ayanore, HT Ayele, E Babaee, U Bacha, A Badawi, M Bagherzadeh, E Bagli, S Balakrishnan, A Balouchi, TW Bärnighausen, RJ Battista, M Behzadifar, BB Bekele, YB Belay, YM Belayneh, KKS Berfield, A Berhane, E Bernabe, M Beuran, N Bhakta, K Bhattacharyya, B Biadgo, A Bijani, MS Bin Sayeed, C Birungi, C Bisignano, H Bitew, T Bjørge, A Bleyer, KA Bogale, HA Bojia, AM Borzì, C Bosetti, IR Bou-Orm, H Brenner, JD Brewer, AN Briko, NI Briko, MT Bustamante-Teixeira, ZA Butt, G Carreras, JJ Carrero, F Carvalho, C Castro, F Castro, F Catalá-López, E Cerin, Y Chaiah, WF Chanie, VK Chattu, P Chaturvedi, NS Chauhan, M Chehrazi, PP-C Chiang, TY Chichiabellu, OG Chido-Amajuoyi, O Chimed-Ochir, J-YJ Choi, DJ Christopher, D-T Chu, M-M Constantin, VM Costa, E Crocetti, CS Crowe, MP Curado, SMA Dahlawi, G Damiani, AH Darwish, A Daryani, J das Neves, FM Demeke, AB Demis, BW Demissie, GT Demoz, E Denova-Gutiérrez, A Derakhshani, KS Deribe, R Desai, BB Desalegn, M Desta, S Dey, SD Dharmaratne, M Dhimal, D Diaz, MTT Dinberu, S Djalalinia, DT Doku, TM Drake, M Dubey, E Dubljanin, EE Duken, H Ebrahimi, A Effiong, A Eftekhari, I El Sayed, MES Zaki, SI El-Jaafary, Z El-Khatib, DA Elemineh, H Elkout, RG Ellenbogen, A Elsharkawy, MH Emamian, DA Endalew, AY Endries, B Eshrati, I Fadhil, V Fallah, M Faramarzi, MA Farhangi, A Farioli, F Farzadfar, N Fentahun, E Fernandes, GT Feyissa, I Filip, F Fischer, JL Fisher, LM Force, M Foroutan, M Freitas, T Fukumoto, ND Futran, S Gallus, FG Gankpe, RT Gayesa, TT Gebrehiwot, GG Gebremeskel, GA Gedefaw, BK Gelaw, B Geta, S Getachew, KE Gezae, M Ghafourifard, A Ghajar, A Ghashghaee, A Gholamian, PS Gill, TTG Ginindza, A Girmay, M Gizaw, RS Gomez, SV Gopalani, G Gorini, BNG Goulart, A Grada, M Ribeiro Guerra, ALS Guimaraes, PC Gupta, R Gupta, K Hadkhale, A Haj-Mirzaian, RR Hamadeh, S Hamidi, LK Hanfore, JM Haro, M Hasankhani, A Hasanzadeh, HY Hassen, RJ Hay, SI Hay, A Henok, NJ Henry, C Herteliu, HD Hidru, CL Hoang, MK Hole, P Hoogar, N Horita, HD Hosgood, M Hosseini, M Hosseinzadeh, M Hostiuc, S Hostiuc, M Househ, MM Hussen, B Ileanu, MD Ilic, K Innos, SSN Irvani, KR Iseh, SMS Islam, F Islami, N Jafari Balalami, M Jafarinia, L Jahangiry, MA Jahani, N Jahanmehr, M Jakovljevic, SL James, M Javanbakht, S Jayaraman, SH Jee, E Jenabi, RP Jha, JB Jonas, J Jonnagaddala, T Joo, SB Jungari, M Jürisson, A Kabir, F Kamangar, A Karch, N Karimi, A Karimian, A Kasaeian, GG Kasahun, B Kassa, TD Kassa, MW Kassaw, A Kaul, PN Keiyoro, AG Kelbore, AA Kerbo, YS Khader, M Khalilarjmandi, EA Khan, G Khan, Y-H Khang, K Khatab, A Khater, M Khayamzadeh, M Khazaee-Pool, S Khazaei, AT Khoja, MH Khosravi, J Khubchandani, N Kianipour, D Kim, YJ Kim, A Kisa, S Kisa, K Kissimova-Skarbek, H Komaki, A Koyanagi, KJ Krohn, BK Bicer, N Kugbey, V Kumar, D Kuupiel, C La Vecchia, DP Lad, EA Lake, AM Lakew, DK Lal, FH Lami, Q Lan, S Lasrado, P Lauriola, JV Lazarus, J Leigh, CT Leshargie, Y Liao, MA Limenih, S Listl, AD Lopez, PD Lopukhov, R Lunevicius, M Madadin, S Magdeldin, HMA El Razek, A Majeed, A Maleki, R Malekzadeh, A Manafi, N Manafi, WA Manamo, M Mansourian, MA Mansournia, LG Mantovani, S Maroufizadeh, SMS Martini, TP Mashamba-Thompson, BB Massenburg, MT Maswabi, MR Mathur, C McAlinden, M McKee, HAA Meheretu, R Mehrotra, V Mehta, T Meier, YA Melaku, GG Meles, HG Meles, A Melese, M Melku, PTN Memiah, W Mendoza, RG Menezes, S Merat, TJ Meretoja, T Mestrovic, B Miazgowski, T Miazgowski, KMM Mihretie, TR Miller, EJ Mills, SM Mir, H Mirzaei, HR Mirzaei, R Mishra, B Moazen, DK Mohammad, KA Mohammad, Y Mohammad, AM Darwesh, A Mohammadbeigi, H Mohammadi, M Mohammadi, M Mohammadian, A Mohammadian-Hafshejani, M Mohammadoo-Khorasani, R Mohammadpourhodki, AS Mohammed, JA Mohammed, S Mohammed, F Mohebi, AH Mokdad, L Monasta, Y Moodley, M Moosazadeh, M Moossavi, G Moradi, M Moradi-Joo, M Moradi-Lakeh, F Moradpour, L Morawska, J Morgado-da-Costa, N Morisaki, SD Morrison, A Mosapour, SM Mousavi, AA Muche, OSS Muhammed, J Musa, AR Nabhan, M Naderi, AJ Nagarajan, G Nagel, A Nahvijou, G Naik, F Najafi, L Naldi, HS Nam, N Nasiri, J Nazari, I Negoi, S Neupane, PA Newcomb, HA Nggada, JW Ngunjiri, CT Nguyen, L Nikniaz, DNA Ningrum, YL Nirayo, MR Nixon, CA Nnaji, M Nojomi, S Nosratnejad, MN Shiadeh, MS Obsa, R Ofori-Asenso, FA Ogbo, I-H Oh, AT Olagunju, TO Olagunju, MM Oluwasanu, AE Omonisi, OE Onwujekwe, AM Oommen, E Oren, DDV Ortega-Altamirano, E Ota, SS Otstavnov, MO Owolabi, M P A, JR Padubidri, S Pakhale, AH Pakpour, A Pana, E-K Park, H Parsian, T Pashaei, S Patel, ST Patil, A Pennini, DM Pereira, C Piccinelli, JD Pillay, M Pirestani, F Pishgar, MJ Postma, H Pourjafar, F Pourmalek, A Pourshams, S Prakash, N Prasad, M Qorbani, M Rabiee, N Rabiee, A Radfar, A Rafiei, F Rahim, M Rahimi, MA Rahman, F Rajati, SM Rana, S Raoofi, GK Rath, DL Rawaf, S Rawaf, RC Reiner, AMN Renzaho, N Rezaei, A Rezapour, AI Ribeiro, D Ribeiro, L Ronfani, EM Roro, G Roshandel, A Rostami, RS Saad, P Sabbagh, S Sabour, B Saddik
Importance: Cancer and other noncommunicable diseases (NCDs) are now widely recognized as a threat to global development. The latest United Nations high-level meeting on NCDs reaffirmed this observation and also highlighted the slow progress in meeting the 2011 Political Declaration on the Prevention and Control of Noncommunicable Diseases and the third Sustainable Development Goal. Lack of situational analyses, priority setting, and budgeting have been identified as major obstacles in achieving these goals. All of these have in common that they require information on the local cancer epidemiology. The Global Burden of Disease (GBD) study is uniquely poised to provide these crucial data. Objective: To describe cancer burden for 29 cancer groups in 195 countries from 1990 through 2017 to provide data needed for cancer control planning. Evidence Review: We used the GBD study estimation methods to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life-years (DALYs). Results are presented at the national level as well as by Socio-demographic Index (SDI), a composite indicator of income, educational attainment, and total fertility rate. We also analyzed the influence of the epidemiological vs the demographic transition on cancer incidence. Findings: In 2017, there were 24.5 million incident cancer cases worldwide (16.8 million without nonmelanoma skin cancer [NMSC]) and 9.6 million cancer deaths. The majority of cancer DALYs came from years of life lost (97%), and only 3% came from years lived with disability. The odds of developing cancer were the lowest in the low SDI quintile (1 in 7) and the highest in the high SDI quintile (1 in 2) for both sexes. In 2017, the most common incident cancers in men were NMSC (4.3 million incident cases); tracheal, bronchus, and lung (TBL) cancer (1.5 million incident cases); and prostate cancer (1.3 million incident cases). The most common causes of cancer deaths and DALYs for men were TBL cancer (1.3 million deaths and 28.4 million DALYs), liver cancer (572 000 deaths and 15.2 million DALYs), and stomach cancer (542 000 deaths and 12.2 million DALYs). For women in 2017, the most common incident cancers were NMSC (3.3 million incident cases), breast cancer (1.9 million incident cases), and colorectal cancer (819 000 incident cases). The leading causes of cancer deaths and DALYs for women were breast cancer (601 000 deaths and 17.4 million DALYs), TBL cancer (596 000 deaths and 12.6 million DALYs), and colorectal cancer (414 000 deaths and 8.3 million DALYs). Conclusions and Relevance: The national epidemiological profiles of cancer burden in the GBD study show large heterogeneities, which are a reflection of different exposures to risk factors, economic settings, lifestyles, and access to care and screening. The GBD study can be used by policy makers and other stakeholders to develop and improve national and local cancer control in order to achieve the global targets and improve equity in cancer care.

Funding

The Institute for Health Metrics and Evaluation received funding from the Bill & Melinda Gates Foundation.

History

Citation

JAMA Oncology, 2019

Author affiliation

/Organisation/COLLEGE OF SOCIAL SCIENCES, ARTS AND HUMANITIES/School of Business

Version

  • VoR (Version of Record)

Published in

JAMA Oncology

Publisher

American Medical Association (AMA)

eissn

2374-2445

Acceptance date

2019-04-30

Copyright date

2019

Available date

2019-10-02

Publisher version

https://jamanetwork.com/journals/jamaoncology/fullarticle/2752381

Language

en

Usage metrics

    University of Leicester Publications

    Categories

    No categories selected

    Keywords

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC